All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The Psoriasis and Psoriatic Arthritis Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Psoriasis and Psoriatic Arthritis Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Psoriasis and Psoriatic Arthritis Hub cannot guarantee the accuracy of translated content. The Psoriasis and Psoriatic Arthritis Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Alice GottliebSteering Committee Member

Alice Gottlieb is a Clinical Professor of Dermatology at the Icahn School Of Medicine at Mount Sinai, Union Square, New York, US.She is triple-boarded in dermatology, rheumatology, and internal medicine and has a PhD in immunology From from The Rockefeller University. 

Professor Gottlieb founded the Dermatology Residency Program at Tufts Medical Center and the Dermatology Division at UMDNJ-Robert Wood Johnson Medical School. She is also the founder and president of the IDEOM (International Dermatology Outcomes Measures) group. Throughout her career, Gottlieb has focused on the pathogenesis and treatment of psoriasis and psoriatic arthritis, and was the first to publish a study that demonstrated the efficacy of TNF blockers as monotherapy in psoriasis, leading to TNF blockers being approved for use and resulting in significant changes to the way psoriasis is treated.